MREO Mereo BioPharma Group plc Stock Quote

MREO [NASD]

Healthcare | Biotechnology | United Kingdom

Index	-	P/E	-	EPS (ttm)	-7.55	Insider Own	0.24%	Shs Outstand	110.95M	Perf Week	-7.77%
Market Cap	210.80M	Forward P/E	-	EPS next Y	-11.50	Insider Trans	0.00%	Shs Float	58.77M	Perf Month	-11.21%
Income	-220.70M	PEG	-	EPS next Q	-4.00	Inst Own	82.70%	Short Float	14.24%	Perf Quarter	-31.65%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-2.35%	Short Ratio	10.47	Perf Half Y	-41.90%
Book/sh	1.38	P/B	1.38	EPS next Y	-	ROA	-	Target Price	9.33	Perf Year	-19.83%
Cash/sh	0.69	P/C	2.75	EPS next 5Y	-	ROE	-	52W Range	1.73 - 4.71	Perf YTD	-46.93%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-59.67%	Beta	-
Dividend %	-	Quick Ratio	3.00	Sales past 5Y	-	Gross Margin	-	52W Low	9.83%	ATR	0.14
Employees	50	Current Ratio	3.00	Sales Q/Q	-	Oper. Margin	-	RSI (14)	35.68	Volatility	9.69% 6.70%
Optionable	Yes	Debt/Eq	1.64	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.93	Prev Close	2.06
Shortable	Yes	LT Debt/Eq	1.06	Earnings	-	Payout	-	Avg Volume	799.50K	Price	1.90
Recom	1.30	SMA20	-14.70%	SMA50	-16.75%	SMA200	-36.56%	Volume	741,285	Change	-7.77%

May-05-21

Initiated

BTIG Research

Buy

$10

Apr-05-21

Initiated

Needham

Buy

$10

Nov-09-21 08:00AM	Mereo BioPharma to Present at Two Upcoming Investor Conferences GlobeNewswire
Nov-04-21 09:00AM	Data from Investigator-sponsored Trial of Mereo BioPharmas alvelestat in Bronchiolitis Obliterans Syndrome (BOS) Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Oct-31-21 10:30AM	2 Growth Stocks That Could Deliver 1,000% Returns Motley Fool
Oct-26-21 10:26AM	Hedge Funds Are Crazy About Mereo BioPharma Group plc (MREO) Insider Monkey
08:00AM	Mereo BioPharma Receives U.S. Orphan Drug Designation for alvelestat in the Treatment of alpha-1 antitrypsin deficiency GlobeNewswire
Oct-13-21 08:00AM	Mereo BioPharma, the Osteogenesis Imperfecta Federation Europe (OIFE) and the Osteogenesis Imperfecta Foundation (OIF) announces completion of the IMPACT Survey enrollment GlobeNewswire
Oct-01-21 04:31PM	Mereo BioPharma and Ultragenyx Present Data from the Phase 2b ASTEROID Study of UX143 (setrusumab) in Osteogenesis Imperfecta (OI) at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting GlobeNewswire +7.02%
Sep-20-21 08:00AM	Mereo BioPharma Announces Appointment of Pierre Jacquet, M.D., Ph.D. to Board of Directors GlobeNewswire -5.30%
Sep-09-21 08:00AM	Mereo BioPharma to Participate in Three Upcoming Investor Conferences GlobeNewswire
Aug-02-21 08:00AM	Mereo BioPharma to Participate in a Fireside Chat at the BTIG Virtual Biotechnology Conference GlobeNewswire
Jul-19-21 07:04PM	Hedge Funds Are Crazy About Mereo BioPharma Group plc (MREO) Insider Monkey
Jun-02-21 09:45AM	Mereo's Alvelestat Shows Encouraging Biomarker Data In Bronchiolitis Obliterans Syndrome Benzinga
08:00AM	Mereo BioPharma Announces Positive Desmosine Biomarker Data from an Interim Analysis of an Investigator Initiated Study of alvelestat in Bronchiolitis Obliterans Syndrome (BOS) GlobeNewswire
May-27-21 08:00AM	Mereo BioPharma to Participate in a Fireside Chat at the Jefferies 2021 Virtual Healthcare Conference GlobeNewswire
May-04-21 08:00AM	Mereo BioPharma to Hold Virtual R&D Day on Thursday, May 13, 2021 GlobeNewswire
Apr-30-21 08:00AM	Mereo BioPharma and Cancer Focus Fund Announce Partnership for Phase 1b/2 Study of Etigilimab in Clear Cell Ovarian Cancer GlobeNewswire
Apr-08-21 08:30AM	Mereo BioPharma to Present at the 20th Annual Needham Virtual Healthcare Conference GlobeNewswire
Mar-31-21 05:02PM	Mereo BioPharma Reports Full Year 2020 Financial Results and Recent Highlights GlobeNewswire
Feb-25-21 11:33AM	Billionaire Ken Griffin Pulls the Trigger on These 2 Penny Stocks TipRanks
Feb-18-21 07:00AM	Mereo BioPharma to Participate in a Fireside Chat at the 10th Annual SVB Leerink Global Healthcare Conference GlobeNewswire +9.02%
Feb-12-21 12:41PM	Mereo BioPharma Group plc Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters Option to Purchase Additional American Depositary Shares GlobeNewswire -5.29%
Feb-10-21 07:00AM	Mereo BioPharma Group plc Announces Pricing of Public Offering of American Depositary Shares GlobeNewswire
Feb-09-21 04:03PM	Mereo BioPharma Group plc Announces Proposed Public Offering of American Depositary Shares GlobeNewswire
Dec-21-20 10:26AM	Company News for Dec 21, 2020 Zacks
Dec-18-20 11:15AM	Ultragenyx (RARE), Mereo Ink Deal for Bone Disease Candidate Zacks +62.90%
07:45AM	The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data Benzinga
Dec-17-20 04:05PM	Ultragenyx and Mereo BioPharma Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta GlobeNewswire
04:05PM	Mereo BioPharma and Ultragenyx Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta GlobeNewswire
Dec-15-20 01:00PM	Mereo BioPharma Provides Update on AIM Delisting and Continued Listing of its ADSs on Nasdaq, and Provides Update on agreements with Silicon Valley Bank and Kreos Capital GlobeNewswire +8.46%
Dec-07-20 10:59PM	Is MREO A Good Stock To Buy Now? Insider Monkey
Nov-23-20 07:05AM	Mereo BioPharma Appoints Suba Krishnan, M.D. as Senior Vice President of Clinical Development GlobeNewswire
Nov-16-20 07:00AM	Mereo BioPharma to Hold Virtual R&D Day on Tuesday, November 24, 2020 GlobeNewswire
Nov-10-20 07:23AM	Mereo BioPharma to Present at the Stifel 2020 Virtual Healthcare Conference GlobeNewswire
Oct-20-20 07:00AM	Mereo BioPharma Appoints Christine Fox as Chief Financial Officer and Heidi Petersen as Senior Vice President, Regulatory Affairs GlobeNewswire
Oct-19-20 07:00AM	Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT) GlobeNewswire +5.37%
Sep-29-20 07:00AM	Mereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2020 and Provides Corporate Update GlobeNewswire
Sep-24-20 07:00AM	Mereo BioPharma Receives FDA Rare Pediatric Disease Designation for Setrusumab for the Treatment of Osteogenesis Imperfecta GlobeNewswire
Sep-16-20 08:00AM	Mereo BioPharma to Announce Interim Financial Results for the Six Months Ended June 30, 2020 and Host Conference Call on September 29, 2020 GlobeNewswire
Sep-04-20 05:08AM	What Type Of Shareholders Own The Most Number of Mereo BioPharma Group plc (LON:MPH) Shares? Simply Wall St.
Aug-25-20 07:00AM	Mereo BioPharma Announces Initiation of Placebo-Controlled Phase 1b/2 Clinical Trial with Alvelestat in COVID-19 Respiratory Disease GlobeNewswire
Aug-17-20 03:30PM	Billionaire Steven Cohen Pulls the Trigger on These 3 Penny Stocks TipRanks
Jun-30-20 07:00AM	Mereo BioPharma Strengthens Management Team; Appoints John Lewicki, PhD, as Chief Scientific Officer and Ann Kapoun, PhD, as SVP of Translational Research and Development GlobeNewswire
Jun-16-20 07:00AM	Mereo BioPharma Announces Financial Results for the Year Ended December 31, 2019 GlobeNewswire
Jun-04-20 07:00AM	Mereo BioPharma Announces Completion of $70 Million Private Placement GlobeNewswire +55.61%
Mar-27-20 08:00AM	Business Update and Directorate Change GlobeNewswire -10.89%
Feb-28-20 07:00AM	Mereo BioPharma Announces Positive Feedback from Type B End-of-Phase 2 Meeting with the FDA and Outlines Pivotal Phase 3 Pediatric Study Design for Setrusumab in Osteogenesis Imperfecta GlobeNewswire
Feb-19-20 07:21AM	The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA Benzinga +12.27%
03:00AM	Mereo BioPharma Announces Equity Investment of $3 Million from New U.S. Institutional Investor GlobeNewswire
Feb-12-20 08:00AM	Mereo BioPharma Announces Update on Distribution Related to Contingent Value Rights Following Recent Oncologie Licensing Agreement for Navicixizumab GlobeNewswire
Feb-11-20 07:23AM	The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology Benzinga -9.00%
Feb-10-20 07:00AM	Mereo BioPharma Enters into a $5 Million Convertible Equity Financing with Novartis and Announces a Securities Purchase Agreement with Aspire Capital Fund, LLC for up to $28 Million GlobeNewswire +28.18%
Jan-14-20 07:00AM	Mereo BioPharma Announces Additional Positive Data from Phase 2b ASTEROID Study of Setrusumab in Adults with Osteogenesis Imperfecta and Provides Update on Regulatory Progress GlobeNewswire
Jan-13-20 07:00AM	Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab GlobeNewswire +7.62%
Nov-11-19 06:30AM	Mereo BioPharmas Setrusumab Demonstrates Dose-Dependent Bone Building and Trend in Fracture Reduction in Phase 2b ASTEROID Study in Adults with Osteogenesis Imperfecta GlobeNewswire -13.58%
Oct-09-19 08:18AM	Mereo BioPharma Sees Hammer Chart Pattern: Time to Buy? Zacks
Oct-07-19 08:00AM	Mereo BioPharma Receives FDA Fast Track Designation for Navicixizumab for the Treatment of Heavily Pretreated Ovarian Cancer GlobeNewswire +7.48%
Sep-17-19 07:00AM	Mereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2019 and Provides Corporate Update GlobeNewswire
Sep-10-19 08:00AM	Mereo BioPharma to Announce Interim Financial Results for the Six Months Ended June 30, 2019 and Provide Corporate Update on September 17, 2019 GlobeNewswire -5.85%
Sep-04-19 08:00AM	Mereo BioPharma Announces Setrusumab 6-Month Phase 2b Data in Osteogenesis Imperfecta Selected for Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research (ASBMR) 2019 Annual Meeting GlobeNewswire +16.25%
Jul-16-19 08:00AM	Mereo BioPharma Appoints Richard Francis as Head of Pharmaceutical Development GlobeNewswire
Jul-15-19 08:00AM	Mereo BioPharma Announces Successful Type B Meeting with U.S. FDA and Outlines Accelerated Approval Pathway for Navicixizumab in Advanced Ovarian Cancer GlobeNewswire +12.16%
Jun-14-19 08:47AM	The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA Benzinga
Jun-13-19 08:00AM	Mereo BioPharma Group plc (Mereo or the Company or the Group) Update on Etigilimab (TIGIT) Partnership GlobeNewswire -13.01%
May-30-19 07:33AM	The Daily Biotech Pulse: Unity Biotech Licenses Anti-Aging Protein, Strong Results For Mereo's Brittle Bone Disease Drug Benzinga
02:00AM	Mereo BioPharma Group plc Announces Positive Early 6 Month Data from the Open Label Arm of the Phase 2b Clinical Study in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with the Anti-Sclerostin Antibody, BPS-804 (setrusumab) GlobeNewswire
May-03-19 12:09PM	Mereo BioPharma Group plc (Mereo or the Company or the Group) Intention to Purchase Shares by Trustee of Employee Benefit Trust GlobeNewswire
Apr-29-19 02:00AM	Mereo BioPharma Group Plc ("Mereo" or the "Company" or the "Group") Preliminary Results for the Year Ended December 31, 2018 -- Strong Operational Progress GlobeNewswire
Apr-26-19 08:00AM	Mereo Biopharma to Announce Preliminary Results for the Full Year 2018 and Host Conference Call on April 29, 2019 GlobeNewswire
Apr-24-19 09:30AM	Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Admission to trading on AIM of New Shares and initiation of trading on Nasdaq of American Depositary Shares GlobeNewswire

Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience